ADC Therapeutics SA (ADCT) Tops Q2 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Wall St futures dip as tech stocks take a breather
- Oil steadies as Middle East crude exports rise and G7 to release stocks
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
August 13, 2026 7:30 AM EDTSecond quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026
LOTIS-7, LOTIS-5 and MZL IIT data submitted for presentation at ASH
Company evaluating regulatory path for ZYNLONTA® to obtain full approval and advance into earlier lines of DLBCL following LOTIS-5 pre-sBLA meeting
Company to host conference call today at 8:30 a.m. EDT
LAUSANNE, Switzerland, Aug. 13,... More
